Search
for
Sort by
Research 211–240 of 1000+
- Role of Polyphenols in Dermatological Diseases: Exploring Pharmacotherapeutic Mechanisms and Clinical Implications
- Autophagy: Guardian of Skin Barrier
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Exploring Mast Cell–CD8 T Cell Interactions in Inflammatory Skin Diseases
- Nanomaterials in hair care and treatment
- Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and Vaccine Development
- Applications of Antioxidant Nanoparticles in Immune-Mediated Inflammatory Diseases
- Autoimmune Skin Diseases in the Era of COVID-19: Pathophysiological Insights and Clinical Implications
- The expanding impact of T-regs in the skin
- Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
- A Current Diagnostic and Therapeutic Challenge: Tinea Capitis
- Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin
- Annual Convention in the Time of COVID
- Common Skin Diseases and Metabolic Syndrome: A Proinflammatory Chemokine Perspective
- Novel Technologies for Exploring the Skin–Brain Axis
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Unraveling Translational Insights into Systemic Multi-Organ Toxicity of Cytosine Arabinoside (Ara-C): A Systematic Review of Preclinical Animal Evidence
- Do Syrian conflict survivors show novel chronic cutaneous sequelae from chlorine gas exposure: A case report and literature review
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Immune niches for hair follicle development and homeostasis
- Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- DIETHYLPROPION
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Anthelminthic drugs
- Cytostatics and immunosuppressive drugs
- Atlas of Geriatric Dermatology
- Pathophysiology of the Behçet's Disease
- Ruxolitinib found to cause eyelash growth: a case report
- Innovations in skin microphysiological systems for nonclinical testing and FDA modernization